Genomic Health - Posters and Abstracts

Home

Logon

About Genomic Health

Oncotype DX in Breast Cancer

Genomics in Cancer

Products and Services

Press Room

Press Releases

Scientific Publications

Posters and Abstracts

Downloadable Files

Investors

Careers at Genomic Health

Posters and Abstracts

44th ASCO Annual Meeting (2008)

Chicago, Ill

Abstract #3512 -- Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer. (J. B. Baker, D. Dutta, D. Watson, T. Maddala, S. Shak, E. K. Rowinsky, L. Xu, E. Clark, D. J. Mauro, S. Khambata-Ford)

Abstract #557 -- Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197. (L. J. Goldstein, R. J. Gray, R. Bugarini, S. Shak, S. S. Badve, F. L. Baehner, N. E. Davidson, G. W. Sledge, J. A. Sparano, The North American Breast Cancer Intergroup)

30th Annual San Antonio Breast Cancer Symposium (2007)

San Antonio, TX

Abstract #10 -- Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal, node-positive, ER-positive breast cancer. (Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Yoshizawa C, Baehner FL, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Allred C, Osborne K, Hayes D)

Abstract #63 -- Prognostic utility of the 21-gene assay compared with Adjuvant! in hormone receptor (HR) positive operable breast cancer with 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of intergroup trial E2197. (L Goldstein, P Ravdin, R Gray, C Yoshizawa, B Childs, S Rowley, S Shak, S Badve, FL Baehner, N Davidson, GW Sledge, JA Sparano)

Abstract #3028 -- Gene expression by standardized quantitative RT-PCR in the special histologic subtypes of estrogen receptor-positive invasive breast cancer. (FL Baehner, D Watson, JT Ballard, G Palmer, S Shak)

Abstract #5029 -- Estrogen receptor and breast cancer survival in a Kaiser Permanente population-based study: Comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry. (LA Habel, N Achacoso, T Maddala, C Alexander, FL Baehner, S Shak, C Quesenberry, AM Gown, LC Goldstein)

Abstract #1092 -- Prospective multi-center study of the impact of the 21-gene Recurrence Score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. (PB Mumby, SS Lo, J Norton, J Smerage, K Joseph, HK Chew, D Hayes, KS Albain)

Abstract #1043 -- Recurrence Score by Oncotype DX evaluated on the primary breast tumor predicts the 2-year survival after first relapse. (G Bianchini, M Zambetti, P Mariani, A Moliterni, G Bianchi, G Mariani, A Fasolo, ML Carcangiu, P Valagussa, L Gianni)

Abstract #3082 -- Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. (C Erb, KR Fox, M Patel, K Hook, A DeMichele, C Kaplan, S Domchek)

Abstract #2061 -- A retrospective analysis of the impact of Oncotype DX low Recurrence Score results on treatment decisions in a single academic breast cancer center. (H Liang, AM Brufsky, BB Lembersky, P Rastogi, VG Vogel)

2007 ASCO Breast Cancer Symposium

San Francisco, CA

Abstract #106 -- Use of estrogen receptor (ER) expression by quantitative RT-PCR to identify an ER-negative subgroup by IHC who might benefit from hormonal therapy. (Bianchini G, Zambetti M, Pusztai L, Carcangiu M, Valagussa P, Gianni L.)

Abstract #27 -- Asssociation of individual genes with risk of relapse in operable breast cancer: Analysis of E2197. (Sparano JA, Goldstein L, Childs B, Yoshizawa C, Shak S, Baker J, Rowley S, Davidson N, Badve S, Sledge Jr. GW, Gray R.)

Abstract #87 -- ER and PR assessment in ECOG 2197: Comparison of locally determined IHC with centrally determined IHC and quantitative RT-PCR. (Badve SS, Baehner FL, Gray R, Childs B, Maddala T, Liu M, Rowley S, Davidson N, Shak S, Sledge Jr. GW, Sparano JA.)

Abstract #88 -- A Kaiser-Permanente population-based study of ER and PR expression by the standard method, immunohistochemistry (IHC), compared to a new method, quantitative reverse transcription polymerase chain reaction (RT-PCR). (Baehner FL, Maddala T, Alexander C, Gown A, Goldstein LC, Achacoso NS, Shak S, Quesenberry CP, Habel LA.)

ASCO 2007

Chicago, IL

Abstract #526 -- Prognostic utility of the 21-gene assay in hormone receptor (HR) positive operable breast cancer and 0-3 positive axillary nodes treated with adjuvant chemohormonal therapy (CHT): An analysis of intergroup trial E2197. (Goldstein LJ, Gray R, Childs B, Watson D, Rowley S, Shak S, Badve S, Davidson NE, Sledge GW, Sparano JA)

Abstract #577 -- Prospective multi-center study of the impact of the 21-gene Recurrence Score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. (Lo SS, Norton J, Mumby PB, Smerage J, Kash J, Chew HK, Hayes D, Epstein A, Albain KS)

29th Annual San Antonio Breast Cancer Symposium (2006)

San Antonio, TX

Abstract #3116 -- A comparison of estrogen receptor (ER) measurement by three methods in node-negative, estrogen receptor (ER)-positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PCR. (Kim C, Tang G, Baehner FL, Watson D, Costantino JP, Paik S, Shak S, Wolmark N)

Abstract #6039 -- The impact on the Recurrence Score due to patient variation in the quantitative expression of individual genes or gene groups. (Watson D, Palmer G, Baker J, Shak S)

Abstract #6111 -- Relationship between proliferation genes and expression of hormone and growth factor receptors: Quantitative RT-PCR in 10,618 breast cancers. (Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D)

Abstract #6118 -- Subtypes of breast cancer defined by standardized quantitative RT-PCR analysis of 10,618 tumors. (Shak S, Baehner FL, Palmer G, Ballard JT, Baker J, Watson D)

Abstract #45 -- Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. (Baehner FL, Habel LA, Quesenberry CP, Capra A, Tang G, Paik S, Wolmark N, Watson D, Shak S)

Association for Molecular Pathology 2006 Annual Meeting

Orlando, Florida

Poster #ST23 -- Analytical validation for the Oncotype DX breast cancer assay, a high complexity, multi-analyte molecular diagnostic test service. (Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Clark K, Watson D)

ASCO 2006

Atlanta, GA

Abstract #3518 -- Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. (O'Connell MJ, Paik S, Yothers G, Costantino JP, Cowens JW, Clark KM, Baker J, Hackett J, Watson D, Wolmark N )

Abstract #538 -- Gene expression profiles in formalin-fixed, paraffin- embedded (FFPE) core biopsies predict docetaxel chemosensitivity. (Chang JC, Makris A, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Sexton K, Osborne CK, Shak S)

Abstract #6024 -- 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) breast cancer: An economic analysis including prognostic and predictive information. (Cosler LE, Kuderer NM, Hornberger J, Lyman GH)

AACR 2006

Washington, DC

Abstract #3604 -- Multiple GSTM gene family members are recurrence risk markers in breast cancer. (Kiefer M, Hoyt K, Hackett J, Walker MG, Baker J)

28th Annual San Antonio Breast Cancer Symposium (2005)

San Antonio, TX

Abstract #2049 -- Impact of Oncotype DX on decision-making in breast cancer clinical practice. (Oratz R, Paul D, Cohn A, Sedlacek S)

Abstract #310 -- Measurement of gene expression using tissue microarray cores of paraffin embedded breast cancer tissue. (Baker J, Salter J, Liu ML, Hackett JR, Cronin M, Shak S, Dowsett M)

Abstract #29 -- Association Between the 21-Gene Recurrence Score assay (RS) and risk of loco-regional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. (Mamounas E, Tang G, Bryant J, Paik S, Shak S, Costantino J, Watson D, Wickerham DL, Wolmark N)

ASCO 2005

Orlando, FL

Abstract #510 -- Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. (Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Watson D, Bryant J, Costantino J, Wolmark N)

Abstract #603 -- Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study. (Habel LA, Quesenberry CP, Jacobs M, Greenberg D, Fehrenbacher L, Alexander C, Baker J, Watson D, Hackett J, Shak S)

27th Annual San Antonio Breast Cancer Symposium (2004)

San Antonio, TX

Abstract #24 -- Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. (Paik S, Shak S, Tang G, Kim C, Joo H, Baker J, Cronin M, Watson D, Bryant J, Costantino J, Wolmark N)

Abstract #104 -- Risk classification of breast cancer patients by the Recurrence Score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. (Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M, Watson D, Bryant J, Wolmark N)

Abstract #2081 -- A 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer (ESBC): An age-specific economic analysis. (Lyman GH, Cosler L, Hornberger J)

ASCO 2004

New Orleans, LA

Abstract #501 -- Gene Expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. (Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Shak S)

Abstract #6036 -- Economic analysis of targeting chemotherapy (CT) using a 21 gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer. (ESBC) (Cosler LE, Hornberger J, Lyman GH)

USCAP 2004

Vancouver, British Columbia

Abstract #83 -- Comparison of ER, PR, HER2, and Ki-67 quantitative expression in formalin-fixed, paraffin-embedded breast carcinomas by RT-PCR with protein expression by immunohistochemistry. (Bitterman P, Watson D, Cronin M, Mosquera JM, Cobleigh M, Baehner R, Shak S, Baker J)

Abstract #80 -- Use of macrodissection in multi-gene RNA analysis of fixed paraffin-embedded tumor tissue. (Baehner R, Hiller B, Kim CY, Alexander C, Liu ML, Pho M, Dutta D, Jeong J, Nguyen A, Walker M, Shak S, Baker J, Paik S)

Abstract #1491 -- Reproducibility of quantitative gene expression analysis by a new RT-PCR assay using fixed paraffin-embedded tissues: A molecular tomographic scanning study. (Cronin M, Watson D, Dutta D, Liu ML, Pho M, Baehner R, Esteban J, Baker J, Shak S)

ASCO 2003

Chicago, IL

Abstract #763 -- Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to Gefitinib, an EGFR kinase inhibitor. (Natale RB, Shak S, Aronson N, Averbuch S, Fox W, Luthringer D, Clark K, Baker J, Cronin M, Agus DB)

Abstract #3466 -- Predicting response to neoadjuvant chemotherapy in invasive breast cancer: Gene expression profiling of paraffin-embedded core biopsy tissue. (Soule SE, Shak S, Baker J, Cronin M, Liu ML, Badve S, Miller KD, Sledge GW)

Abstract #3416 -- Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. (Esteban J, Baker J, Cronin M, Liu ML, Llamas MG, Walker MG, Mena R, Shak S)

Abstract #3415 -- Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffin-embedded tumor tissues. (Cobleigh MA, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Tabesh B, Mosquera J, Walker MG, Shak S)

AACR Oncogenomics 2003

Phoenix, AZ

Gene Expression Profiling of fixed, paraffin-embedded tumor specimens, using a 192 gene panel RT-PCR assay. (Kiefer M, Stephans J, Liu ML, Dutta D, Pho M, Nguyen A, Jeong J, Cronin M, Esteban J)

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2002

Frankfurt, Germany

Strategies to optimise anti-receptor therapies. (Baselga J)

ASCO 2002

Orlando, FL

Abstract #3017 -- Gene expression profiling of fixed paraffin-embedded breast cancer tissues. (Kiefer M, Stephans J, Abulaban S, Shodhan S, Alexander MC, Esteban J)

SABCS 2006 Photo by Todd Buchanan

To open PDF documents, please
download the latest version of
Adobe Acrobat Reader, a free download.


Copyright © 2008 Genomic Health, Inc. All rights reserved.	\| Contact Us \| Site Map \| Privacy \| Terms and Conditions \|